Lipocine Inc. develops pharmaceutical products to treat metabolic and neuroendocrine disorders, focusing on oral delivery solutions for drugs which are poorly bioavailable. Their most advanced candidate is TLANDO, an oral testosterone replacement therapy. They also have several other pipeline candidates, including LPCN 1144, LPCN 1111, LPCN 1148, LPCN 1154, LPCN 2101, and LPCN 1107.